Last updated: February 24, 2026
What is the Drug Identified by NDC 70677-1247?
The drug with NDC 70677-1247 is Ravulizumab-cwvz (Ultomiris), marketed by Alexion, a subsidiary of AstraZeneca. It is a monoclonal antibody that inhibits terminal complement component 5 (C5), used primarily for complement-mediated diseases including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and cold agglutinin disease.
What is the Current Market Landscape?
Market Size and Demand
The global anti-complement monoclonal antibody market was valued at approximately USD 220 million in 2022, with a compounded annual growth rate (CAGR) forecast of 12% until 2030. Key drivers include increased diagnosis, expanded indications, and approval of new therapies.
Disease-Specific Market Data
| Disease |
Estimated Patients |
Treatment Penetration |
Annual Treatment Cost |
Market Potential (2023) |
| Paroxysmal nocturnal hemoglobinuria (PNH) |
4,000 - 6,000 |
80% in developed markets |
USD 500,000 |
USD 15 million - USD 20 million |
| Atypical hemolytic uremic syndrome (aHUS) |
2,500 - 4,000 |
70% |
USD 550,000 |
USD 10 million - USD 15 million |
| Generalized myasthenia gravis |
45,000 |
10% |
USD 60,000 annually |
USD 2.7 million |
Competitive Landscape
The primary competitor is Eculizumab (Soliris) by Alexion/AstraZeneca, with sales exceeding USD 1 billion annually.
Other emerging therapies include Crovalimab and Danicopan, but these are in earlier phases and hold smaller market shares.
Regulatory Status
Ultomiris has received FDA approval for PNH (2018), aHUS (2018), generalized myasthenia gravis (2021), and cold agglutinin disease (2022). It maintains a strong position due to longer dosing intervals compared to Soliris (every 8 weeks versus every 2 weeks).
Price Projections and Revenue Estimates
Current Pricing
The wholesale acquisition cost (WAC) for Ultomiris is approximately USD 573,370 per treatment year for PNH patients. Actual list prices vary based on negotiated discounts and insurance.
Future Price Trends
| Year |
Projected Price per Treatment Year |
Justification |
| 2023 |
USD 573,370 |
Current pricing |
| 2025 |
USD 580,000 - USD 600,000 |
Potential inflation adjustment, competitive price stabilization |
| 2030 |
USD 620,000 - USD 650,000 |
Anticipated inflation, increased demand, potential dossier updates |
Revenue Projections
Assuming a steady increase in treated patient population:
| Year |
Estimated Patients (Global) |
Total Revenue (USD) (approximate) |
| 2023 |
4,000 |
USD 2.3 billion |
| 2025 |
5,500 |
USD 3.3 billion |
| 2030 |
8,000 |
USD 5.2 billion |
Growth assumptions include expanded indication approvals and increased access in developing markets.
Market Risks and Challenges
- Pricing pressures due to increasing biosimilar development.
- Market penetration barriers in regions with limited healthcare access.
- Regulatory changes potentially affecting approval and reimbursement pathways.
- Competitive innovation advancing with newer, potentially more affordable therapies.
Conclusion
Ultomiris maintains a dominant position in the complement inhibition market with high-cost, long-acting formulations. Continued growth hinges on expanding approved indications and geographic reach. Price inflation is expected modestly through 2030, aligning with inflation and market demand.
Key Takeaways
- The drug, Ravulizumab-cwvz, has a large addressable market primarily in PNH and aHUS.
- Current annual treatment costs are approximately USD 573,370.
- Revenue potential could reach USD 5.2 billion by 2030 with increased patient access.
- The competitive landscape is heavily dominated by Soliris, though Ultomiris's dosing schedule provides advantages.
- Pricing pressures and biosimilar entry remain notable risks.
FAQs
1. What are the main indications for Ultomiris?
PNH, aHUS, generalized myasthenia gravis, and cold agglutinin disease.
2. How does Ultomiris differ from Soliris?
Ultomiris is administered less frequently (every 8 weeks vs. every 2 weeks for Soliris), potentially improving patient adherence and reducing administration costs.
3. What factors could influence future pricing?
Market competition, biosimilar entry, regulatory decisions, and healthcare policy changes.
4. Which regions present the largest market opportunities?
North America and Europe dominate current sales; Asia-Pacific presents growth potential due to expanding healthcare infrastructure.
5. What is the primary risk to revenue growth?
Introduction of biosimilars and price competition, alongside reimbursement and regulatory hurdles.
Citations
- National Organization for Rare Disorders. (2022). Paroxysmal nocturnal hemoglobinuria. Retrieved from https://rarediseases.org/rare-diseases/paroxysmal-nocturnal-hemoglobinuria/
- EvaluatePharma. (2022). Anti-Complement Monoclonal Antibodies Market Report.
- U.S. Food and Drug Administration. (2018). FDA approves Ultomiris for PNH. Retrieved from https://www.fda.gov/
- AstraZeneca. (2023). Ultomiris (ravulizumab-cwvz) prescribing information.
- IQVIA. (2023). Global Biotechnology Market Analysis.
